论文部分内容阅读
目的:分析舒利迭联合顺尔宁或布地奈德防治小儿哮喘的临床疗效。方法:选取2012年1月-2014年1月收治的小儿哮喘患儿108例,随机分为研究组和对照组,每组54例。对照组患儿给予舒利迭联合顺尔宁治疗,研究组患儿给予舒利迭联合布地奈德治疗。对比两组患儿的临床治疗效果、肺功能指标,炎症因子指标以及不良反应。结果:研究组患儿治疗3个月和6个月后的哮喘控制率显著高于对照组(P<0.05)。治疗6个月后,研究组患儿的一秒用力呼气容积(FEV1)、用力呼气流量(PEF)、最大呼气中段流量(MMEF)指标显著高于对照组(P<0.05)。治疗6个月后,研究组患儿的免疫球蛋白E(IgE)、白介素4(IL4)、白介素13(IL-13)水平显著降低,γ-干扰素(IFN-γ)水平显著升高(P<0.05)。两组患儿均无严重不良反应,组间比较,差异无统计学意义(P>0.05)。结论:舒利迭联合布地奈德防治小儿哮喘效果更优。
Objective: To analyze the clinical efficacy of seretide combined with sirolimus or budesonide in the prevention and treatment of pediatric asthma. Methods: A total of 108 children with asthma admitted from January 2012 to January 2014 were randomly divided into study group and control group, with 54 cases in each group. Children in the control group were treated with seretide plus cis-ning and children in the study group were given sulpiride combined with budesonide. The clinical effects, lung function, inflammatory factor and adverse reactions in two groups were compared. Results: The control rate of asthma in study group after 3 months and 6 months was significantly higher than that in control group (P <0.05). Six months after treatment, FEV1, PEF and MMEF in study group were significantly higher than those in control group (P <0.05). Six months after treatment, the levels of IgE, IL-4 and IL-13 in the study group were significantly decreased and the levels of IFN-γ were significantly increased P <0.05). There was no serious adverse reaction between the two groups. There was no significant difference between the two groups (P> 0.05). Conclusion: Combination of seretide and budesonide in children with asthma is better.